GTBIF vs TLRY: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
GTBIF is the larger of the two ($1.24B market cap): the incumbent the market prices for continued execution (21.74x forward earnings, beta 1.14). TLRY is the smaller challenger ($283.01M), cheaper on forward earnings (13.48x): more room to run, but more to prove. If you believe GTBIF earns its premium (21.74x forward earnings, so the market expects more from it), GTBIF fits. If you believe in paying less for profit, TLRY fits at 13.48x.
GTBIF vs TLRY: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | GTBIF | TLRY | What it tells you |
|---|---|---|---|
| Market cap | $1.24B | $283.01M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 21.74 | 13.48 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.14 | 2.06 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 7% of range | 0% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.66 | 0.17 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: TLRY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how GTBIF and TLRY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GTBIF and TLRY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GTBIF and TLRY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Green Thumb Industries (GTBIF) do?
Green Thumb Industries is a Chicago-based cannabis company founded in 2014 by Ben Kovler. It grows, processes and sells cannabis under consumer brands such as Rythm (flower and vapes), Dogwalkers (pre-rolls), incredibles (edibles) and Beboe, and it runs roughly 100 to 115 RISE and other branded dispensaries across 14 US markets, including Illinois, Pennsylvania, Florida, New Jersey, Ohio, Minnesota, Connecticut and Nevada. Because cannabis remains federally illegal for adult use, its shares cannot list on a US exchange: they trade over the counter as GTBIF and on the Canadian Securities Exchange as GTII.
What does Tilray Brands (TLRY) do?
Tilray Brands, Inc. is a diversified consumer company best known for cannabis but now spanning four areas: cannabis (medical and adult-use, plus hemp-derived products) across Canada, Europe, and other markets; a large craft beverage business built through acquisitions of SweetWater, Breckenridge, and beer brands and breweries from Anheuser-Busch and Molson Coors; a wellness arm centered on hemp-based products; and a distribution segment. This makes Tilray unusual among cannabis names: it generates substantial real revenue from beer and drinks, giving it a foothold in regulated US consumer markets even where cannabis remains federally illegal. Its fiscal year ends May 31, so its reporting calendar differs from most companies.
GTBIF vs TLRY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- GTBIF drivers: Federal rescheduling and the end of 280E; New adult-use markets and store openings in its footprint.
- TLRY drivers: International medical cannabis growth; Craft beverage scale and diversification.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The main risk is regulatory. For TLRY, the biggest risk is that Tilray remains unprofitable on a net basis and has repeatedly issued new shares, diluting existing holders, a major reason the stock trades at a very low absolute price.
GTBIF or TLRY: which should you pick?
If the story you believe is GTBIF's (Federal rescheduling and the end of 280E), GTBIF is the more direct way to own it; if it is TLRY's (International medical cannabis growth), TLRY is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GTBIF and TLRY guides.
GTBIF vs TLRY: the full fundamentals
GTBIF. At ~$5.69, Green Thumb is valued at roughly 1.0 times trailing sales and about 13.5 times trailing earnings, with enterprise value under six times trailing EBITDA. The forward P/E is higher, near 22x, because consensus expects 2026 EPS of only ~$0.11 before ~$0.36 in 2027. Those multiples are low for a company with ~28% normalized EBITDA margins and positive cash flow, and the gap reflects federal illegality, 280E taxes, OTC-only trading in the US and steady price compression. The next data points are a federal rescheduling decision and the Q4 2026 report, where management has guided revenue flat to slightly down sequentially (consensus ~$323.5M).
TLRY. These figures are approximate and tied to the asOf date; verify live numbers before acting. At about a third of trailing sales and under a fifth of book value, the market is pricing Tilray as a business that may not turn its revenue into profit, after a year in which the shares fell about 79%. The forward P/E near 14 rests on fiscal 2028 consensus EPS of about $0.14, while fiscal 2027 consensus is still a loss of about $(0.13), so small changes in results swing it wildly. The next report, fiscal Q2 2027, is expected around January 7, 2027, with consensus revenue near $265 million; watch cash burn, cannabis revenue trends, the cost program and BrewDog integration more than headline revenue.
Headline figures (approximate, November 2026): GTBIF shows revenue (ttm) ~$1.24B; Q3 2026 ~$324.4M, up ~11%, market cap ~$1.25B at ~$5.69 (Nov 20, 2026), price / sales ~1.0x (EV/EBITDA ~5.8x), p/e (trailing / forward) ~13.5x / ~21.9x; TLRY shows market cap ~$286M (share price ~$1.93), revenue (ttm) ~$963M; fiscal Q1 2027 ~$257M, +23% yoy (BrewDog-driven), profitability Net loss ~$164M TTM; gross margin ~29%; fiscal Q1 2027 adjusted EBITDA ~$9.2M, eps vs estimates Fiscal Q1 2027 ~$(0.02) vs ~$(0.14) est.; fiscal Q4 2026 ~$0.05 vs ~$0.21 est..
The bottom line: GTBIF vs TLRY
GTBIF and TLRY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined GTBIF and TLRY exposure against your real portfolio. It is not an investment adviser.
Wondering how GTBIF or TLRY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Green Thumb Industries
Ask Walnut's AI anything about GTBIF and see how it fits what you own.
FAQ
What is the difference between GTBIF and TLRY?
+
Green Thumb Industries is a Chicago-based cannabis company founded in 2014 by Ben Kovler. Tilray Brands, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is GTBIF or TLRY the better stock?
+
Neither is universally better. GTBIF is the larger incumbent; TLRY is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, GTBIF or TLRY?
+
On forward P/E (as of November 2026), GTBIF trades at 21.74x and TLRY at 13.48x, so TLRY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both GTBIF and TLRY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of GTBIF vs TLRY?
+
GTBIF: The main risk is regulatory. Adult-use cannabis remains a Schedule I substance, so most of Green Thumb's sales still face Section 280E, restricted banking and no access to US stock exchanges. A broader rescheduling decision could be delayed, narrowed or challenged in court, the IRS has not issued complete guidance on how the April 2026 order applies, and management has warned that delays mean continued significant tax liabilities. Price compression is the second risk: gross margin fell roughly eight points in two years to ~45% in Q3 2026, management expects further compression in coming quarters, and new cultivation capacity in states like Illinois, New Jersey and Ohio continues to push prices down. Third, intoxicating hemp-derived THC products, now sold in mainstream retailers, compete for the same customers without cannabis licensing costs or taxes, although management said changes in hemp policy could become a tailwind. Fourth, profitability is lumpy: 2025 GAAP net income leaned on warrant fair-value gains, Q2 2026 GAAP net income was only ~$4.9M, and Q3 2026 was a GAAP net loss of ~$4.8M as SG&A rose. Consensus expects 2026 EPS of only ~$0.11 before a rebound to ~$0.36 in 2027, so the forward multiple depends on that recovery. Finally, GTBIF trades OTC with lower liquidity and higher volatility than listed stocks, many US brokers restrict cannabis names, analyst coverage on Yahoo Finance is thin (two analysts), and founder voting control limits outside shareholder influence. Growth also depends on a short list of state catalysts: Virginia adult-use is not scheduled until mid-2027, Texas timing is uncertain, and Pennsylvania and Florida have repeatedly stalled on adult-use legalization. TLRY: The biggest risk is that Tilray remains unprofitable on a net basis and has repeatedly issued new shares, diluting existing holders, a major reason the stock trades at a very low absolute price. Cannabis legalization, the core long-term catalyst, has stalled in the US and moves slowly elsewhere, so the biggest addressable market may stay closed for years. Cannabis revenue itself fell about 13% year over year in fiscal Q1 2027, operating expenses rose roughly 83%, and quarterly cash burn widened to about $16.5 million, so the core business is not yet carrying its own costs. The Canadian adult-use market is oversupplied and price-competitive, and the craft beer segment faces industry-wide volume softness. Currency swings affect large international sales, and the company relies on acquisitions that carry integration risk. The stock is highly volatile and speculative, sensitive to legalization headlines, and the company explored a reverse stock split to maintain its Nasdaq listing, a reminder of the low share price. The share price fell below $2 in November 2026, and governance is also in question: a November 2026 vote to declassify the board failed despite about 77% support from votes cast, and the company funds some acquisitions through at-the-market share offerings.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GTBIF or TLRY; figures are approximate and dated (as of November 2026). Verify current data before investing.